Congress Demands Answers on Data Privacy Ahead of 23andMe Sale

As news broke of 23andMe’s potential sale to a large pharmaceutical company, concerns about data privacy have come to the forefront.

Congress has now launched an inquiry into the sale, demanding answers from both 23andMe and the potential buyer about how customer data will be protected.

Many are worried about the implications of such a sale, as 23andMe has collected vast amounts of genetic and health data from its customers over the years.

There are fears that this data could be used for purposes beyond what customers originally consented to, such as marketing or research without their knowledge.

Congress is seeking assurances that any sale will not compromise the privacy and security of this sensitive data.

Experts in data privacy and consumer advocacy have also raised concerns about the potential sale, urging Congress to act swiftly to protect consumer rights.

The sale of 23andMe could set a dangerous precedent for how companies handle and profit from personal data, raising important questions about the intersection of technology, healthcare, and privacy.

As the inquiry continues, many are watching closely to see how Congress will address these pressing issues and protect the rights of consumers in an increasingly data-driven world.

Stay tuned for updates on this developing story as more information becomes available.